Premium Content

Switzer Report

Switzer Report leverages Australia's most experienced finance and markets team to provide more in-depth commentary and analysis that can benefit your portfolio. Take a free trial for yourself to find out.

Start Your Free Trial

Expert Stock Picks

Curated recommendations from our analysts

Model Portfolios

Follow our proven investment strategies

In-Depth Analysis

Detailed research on markets & sectors

The Latest from Switzer

‘HOT’ stock: ResMed (RMD)
Switzer Report Subscriber Exclusive
Investing

‘HOT’ stock: ResMed (RMD)

Raymond Chan, Private Adviser & Head of Asian Desk at Morgans, explains why Morgans regards ResMed (RMD) as a BUY.

Maureen Jordan 4 May
Three potential IT ‘A-graders’
Switzer Report Subscriber Exclusive
Investing

Three potential IT ‘A-graders’

Here are three stocks, two with world-leading proprietary software and one with a growing specialisation in providing its clients with the capability and capacity to…

James Dunn 4 May
Buy, Hold, Sell, What the Brokers Say (4 May 2026)
Switzer Report Subscriber Exclusive
Broker Recommendations

Buy, Hold, Sell, What the Brokers Say (4 May 2026)

For the week ending Friday 1 May 2026, FNArena recorded nine upgrades and 10 downgrades from the seven brokers monitored daily across ASX-listed companies.

Rudi Filapek-Vandyck 4 May

Join our newsletter community

Get the latest financial, business, and political expert commentary delivered to your inbox every weekday.

Investing

View All